4.7 Article

A genomic approach identifies sRAGE as a putatively causal protein for asthma

Journal

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
Volume 149, Issue 6, Pages 1992-+

Publisher

MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2021.11.027

Keywords

Asthma; Mendelian randomization; sRAGE; causal inference; Framingham Heart Study; GWAS; protein-trait association; proteomics; genomics

Funding

  1. National Institutes of Health (NIH) [N01-HC-25195]
  2. Division of Intramural Research, National Heart, Lung, and Blood Institute (NHLBI), NIH

Ask authors/readers for more resources

Through this genomic approach, we identified sRAGE as a putatively causal, biologically important, and protective protein in relation to asthma.
Background: Asthma is a complex respiratory condition caused by environmental and genetic factors. Although lower concentrations of the anti-inflammatory protein soluble receptor for advanced glycation end products (sRAGE) have been associated with asthma in humans and mouse models, it is uncertain whether sRAGE plays a causal role in asthma. Objective: We designed a 2-stage study of sRAGE in relation to asthma with association analysis in FHS participants as well as causal inference testing using Mendelian randomization (MR). Methods: We measured plasma levels of sRAGE and performed cross-sectional analysis to examine the association between plasma sRAGE concentration and asthma status in 6546 FHS participants. We then used sRAGE protein advanced glycation end products (pQTLs) derived from a genome-wide association study of plasma sRAGE levels in similar to 7000 FHS participants with UK Biobank asthma genome-wide association study in MR to consider sRAGE as a putatively causal protein for asthma. We also performed replication MR using an externally derived sRAGE pQTL from the INTERVAL study. Last, we conducted colocalization using cis-pQTL variants at the advanced glycosylation end-product specific receptor (AGER) locus with variants from the UK Biobank asthma genome-wide association study. Results: Association analysis revealed that each 1 SD increment in sRAGE concentration was associated with a 14% lower odds of asthma in FHS participants (95% CI 0.76-0.96). MR identified sRAGE as putatively causal for and protective against asthma on the basis of self-reported (odds ratio [per 1 SE increment in inverse-rank-normalized sRAGE] 5 0.97, 95% CI 0.95-0.99; P = .005) and doctor-diagnosed asthma (odds ratio 5 0.97, 95% CI 0.95-0.99; P = .011). Conclusion: Through this genomic approach, we identified sRAGE as a putatively causal, biologically important, and protective protein in relation to asthma. Functional studies in cell/animal models are needed to confirm our findings.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available